Lv71
4990 积分 2023-01-03 加入
The evolving landscape of obesity pharmacotherapy
10小时前
待确认
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
2个月前
已完结
Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy
2个月前
已完结
Facile discovery of surrogate cytokine agonists
2个月前
已完结
Understanding the tumor immune microenvironment (TIME) for effective therapy
3个月前
已完结
More than the sum: How vascular endothelial growth factor inhibition unlocks the full potential of immune checkpoint blockade
3个月前
已完结
Interleukin 2-Based Cancer Immunotherapies: The Discovery of Next-Generation Antibody-Cytokine Bispecific Antibody Drug
4个月前
已完结
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
4个月前
已完结
Rationally Designed Less Toxic SPD‐304 Analogs and Preliminary Evaluation of Their TNF Inhibitory Effects
5个月前
已完结
皖公网安备34019202002308
